20/20 Biolabs (NASDAQ:AIDX – Get Free Report) was upgraded by research analysts at Maxim Group to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
Separately, Wall Street Zen upgraded shares of 20/20 Biolabs to a “hold” rating in a report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, 20/20 Biolabs presently has a consensus rating of “Strong Buy” and a consensus price target of $5.00.
View Our Latest Stock Analysis on AIDX
20/20 Biolabs Price Performance
20/20 Biolabs (NASDAQ:AIDX – Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.54 million for the quarter.
About 20/20 Biolabs
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.
Further Reading
- Five stocks we like better than 20/20 Biolabs
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
